

Learn about common and serious Ebglyss side effects, including eye problems and injection reactions. Know when to call your doctor and how to manage symptoms.
Starting a new medication always comes with questions — especially when it's a biologic injection. If you've been prescribed Ebglyss (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis, here's what to expect in terms of side effects and when you should contact your doctor.
Ebglyss is a biologic medication made by Eli Lilly. It works by blocking interleukin-13 (IL-13), a protein that drives the inflammation, itching, and skin barrier problems behind eczema. It's given as a subcutaneous injection — first every two weeks during loading, then every four weeks for maintenance. For a deeper dive, see our guide on what Ebglyss is and how it's used.
Most people who take Ebglyss tolerate it well. The most frequently reported side effects include:
Eye-related side effects are something Ebglyss shares with other IL-13 inhibitors. If you notice persistent eye discomfort, let your doctor know — they may refer you to an ophthalmologist.
Serious side effects are less common but important to be aware of:
Some groups should be especially mindful:
Here are some practical tips:
For more on how Ebglyss works in your body, check out our mechanism of action guide.
Most Ebglyss side effects are mild and manageable. Eye-related symptoms are the most distinctive — if you notice any changes in your vision or eye comfort, don't ignore them. Stay in regular contact with your dermatologist, and report anything unusual promptly.
Looking for Ebglyss? Visit medfinder.com to check availability near you.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.